Cutaneous Vasculitis with Gut Involvement During Secukinumab Treatment for Psoriatic Arthritis

Vasculitis during certolizumab pegol and secukinumab treatment: Report of two cases

“…Even though biologic agents have a good overall safety profile, various immune-mediated cutaneous adverse events with these agents have been reported. [1][2][3][4][5] Herein, we would like to report two patients who developed leukocytoclastic vasculitis (LCV) under certolizumab pegol and secukinumab treatment, respectively.…”

“…Similar to our patients, LCV cases associated with various biologic agents were reported to have TNF-α inhibitor treatment previously which was switched due to inefficiency. 4,7,9 Therefore, we believe that previous administration of TNF-α inhibitors may possibly be considered as a risk factor to develop LCV under subsequent biologic agent administration. The use of TNF-α inhibitors might have resulted in antidrug antibody formation which can contribute to LCV development.…”

Review of secukinumab‐induced adverse events of special interest and its potential pathogenesis

“…The searches generated 1426 potentially articles that matched our predefined search strategy, of which 55 were included in this review (Figure 1): 2 clinical studies, 11,12 2 review, 9,13 50 case reports 5,6,14–61 and 1 case series, 62 published between 2016 and 2021. More than 1077 patients (aged 18–74 years) experienced AESI after secukinumab treatment for Ps, PsA, AS, spondyloarthritis (SpA), and/or palmoplantar psoriasis (PPP).…”

Multifaceted Secukinumab-induced Colitis

“…Secukinumab-induced adverse effects in the gastrointestinal tract can present with features of CD, UC, ischemic colitis, fulminant colitis and vasculitis. 4,5…”